Navigation Links
Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results
Date:5/18/2010

NANJING, China, May 18 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today reported preliminary unaudited financial results for the quarter ended March 31, 2010.

    Highlights
    -- Total revenue was RMB458.7 million (US$67.2 million) for the first
       quarter of 2010, compared to RMB442.5 million for the same period in
       2009, representing year-over-year growth of 3.7%.
    -- Gross margin for the first quarter of 2010 decreased to 79.7% compared
       to 82.5% for the same period in 2009.
    -- Income from operations was RMB30.9 million (US$4.5 million) for the
       first quarter of 2010, a decrease of 49.5% from RMB61.1 million for the
       same period in 2009.
    -- Net income attributable to Simcere was RMB20.5 million (US$3.0 million)
       for the first quarter of 2010, a decrease of 57.5% from RMB48.2 million
       for the same period in 2009.

"While the first quarter remained challenging, we saw solid revenue growth for our edaravone products and were encouraged by the continuing sales recovery of Endu," said Mr. Jinsheng Ren, Chairman and Chief Executive Officer of Simcere Pharmaceutical Group. "We believe that we will see additional benefits arising from the restructuring of our sales force for the remainder of 2010."

"Recently we were pleased to announce that Simcere's diosmectite passed EU-GMP inspection and that Endu successfully completed the Phase IV clinical study which verified the positive resu
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Simceres Diosmectite API Passes EU-GMP Inspection
2. Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study
3. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Tuesday, March 16, 2010
4. Simcere Receives SFDA Approval to Manufacture and Sell Zanamivir in China
5. Simcere Pharmaceutical Group Provides Update on Jiangsu Yanshen
6. Simcere Pharmaceutical Group Announces Jiangsu Yanshens Voluntary Suspension of Production
7. Simcere Pharmaceutical Group to Acquire Additional Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd.
8. Simcere Pharmaceutical Group Announces Collaboration with OSI Pharmaceuticals
9. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
10. Epix Pharmaceuticals, Inc. Announces Additional Information Concerning the May 28, 2010 Auction Sale of EP-3600 MRI Imaging Agent
11. Isis Pharmaceuticals to Discuss Its Cancer Franchise in a Conference Call on Wednesday, May 19
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014 CytRx Corporation (NASDAQ: ... development company specializing in oncology, today announced the ... evaluating aldoxorubicin compared to topotecan in subjects with ... relapsed or were refractory to prior chemotherapy. Aldoxorubicin ... agent, doxorubicin. CytRx has received Orphan Drug Designation ...
(Date:9/29/2014)... et SAN DIEGO , ... Ltd. (ci-après désignée Daiichi Sankyo) (TSE : 4568) et ... la conclusion d,un accord de fusion définitif en ... totalité des actions ordinaires en circulation d,Ambit Biosciences ... le biais d,une offre publique d,achat qui sera ...
(Date:9/29/2014)... Calif. , Sept. 29, 2014  Bob Pack, ... driver, today called on the California Medical Association to ... Proposition 46 that the San Jose Mercury News called ... "practically everything it wants voters to believe about the ... ad attacks the Prop 46 requirement that doctors check ...
Breaking Medicine Technology:CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 4CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 5Daiichi Sankyo va acquérir Ambit Biosciences 2Daiichi Sankyo va acquérir Ambit Biosciences 3Daiichi Sankyo va acquérir Ambit Biosciences 4Daiichi Sankyo va acquérir Ambit Biosciences 5Daiichi Sankyo va acquérir Ambit Biosciences 6Daiichi Sankyo va acquérir Ambit Biosciences 7Daiichi Sankyo va acquérir Ambit Biosciences 8Daiichi Sankyo va acquérir Ambit Biosciences 9Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 2Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 3Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 4Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 5
(Date:9/30/2014)... 30, 2014 World of Children Award ... of the nonprofit, Friends Without A Border (FWAB) – ... building a hospital in Cambodia that has become the ... first encountered Cambodia’s appalling lack of pediatric healthcare when ... and illnesses during a photography trip in 1993. , ...
(Date:9/30/2014)... 30, 2014 AutoTex PINK ... iconic pink ribbon in support of breast cancer awareness ... for businesses and non-profits to “go pink” -- supporting ... AutoTex PINK is a woman-owned company that is among ... are committed to partnering with their customers to raise ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Teeth replacement ... Dental Art Institute in Oxnard and Thousand Oaks, Calif., ... and tomorrow to provide training on full mouth rehabilitation. ... work, placing implants, providing cosmetic dentistry, correcting bite issues, ... said. , Dr. Jivraj, who has traveled to India ...
(Date:9/30/2014)... Minneapolis, MN (PRWEB) September 30, 2014 ... recognized leader in business technology and services was ... in First Call Effectiveness (FCE) in 2013. This ... devices properly the first time and for an ... longevity. For more than 20 years BEI Services ...
(Date:9/30/2014)... In honor of National Breast Cancer Awareness ... courageous battles, Incredible Veins, Body & Skin is offering ... Cynosure. , “For cancer patients who receive radiation ... on their skin to accurately aim the radiation on ... survivors, they decide to have their tattoo removed as ...
Breaking Medicine News(10 mins):Health News:Nobel Prize For Child Advocates Announces 2014 Health Award Honoree 2Health News:Nobel Prize For Child Advocates Announces 2014 Health Award Honoree 3Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 2Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 3Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 2Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 3Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 4Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 5Health News:Loffler Companies Rated Number One Among U.S. Dealers in Service “First Call Effectiveness” 2Health News:Loffler Companies Rated Number One Among U.S. Dealers in Service “First Call Effectiveness” 3Health News:Incredible Veins, Body & Skin Takes A Stand Against Breast Cancer With PicoSure® By Cynosure 2
... spontaneous preterm birth, according to researchers at Yale School of ... at the Society for Gynecologic Investigation Conference in Reno, Nevada ... cause of illness and death in newborns. A genetic cause ... to occur within families and a high rate of recurrence, ...
... rate due to homicide, HIV disease, accidental injuries and heart ... behind the reduction in the life expectancy gap between blacks ... exist. The study is published in the March 21 issue ... generally been increasing in the United States since at least ...
... apnea having significantly higher serum levels of inflammatory markers, ... have an elevated risk of stroke, according to Japanese ... second issue for March 2007 of the American Journal ... American Thoracic Society. ,Kenji Minoguchi, M.D., Ph.D., ...
... to pay for medical treatment and prescriptions is common ... recovery//, more angina, poorer quality of life and higher ... at Yale School of Medicine. ,The study ... care services or medication were associated with worse patient ...
... is a human tumor virus which causes Kaposi’s sarcoma ... aggressive lymphomas with reported median survival time less than ... University of Helsinki have discovered that activation of the ... KSHV-infected lymphomas. ,The findings by the research ...
... blood sugar levels in women could lead// to cancer. ... of men. ,Dr Par Stattin of Umea University Medical ... over 65,000 persons. ,Writing in the journal Diabetes ... an increased risk of liver, pancreas, colon cancer, as well as ...
Cached Medicine News:Health News:Gene Variants Linked to Preterm Birth in Hispanic Women 2Health News:Black-white Life Expectancy Gap Reduces, Yet Remains Significant 2Health News:NCPAP Decreases Cerebrovascular Risk in OSA Patients 2Health News:NCPAP Decreases Cerebrovascular Risk in OSA Patients 3Health News:Due to Cost, Heart Attack Patients Often Avoid Follow-up Care and Medication 2Health News:A Novel Treatment for KSHV-infected Lymphomas 2